The peptideGLP-1TRTdoseweightsleephealthlevel tracker built on real data and intelligence.

Phase 2 obesity trial. 338 adults randomized to retatrutide or placebo. Mean body-weight change at 48 weeks: −17.5% on 12-mg retatrutide vs −2.1% on placebo. Dose-dependent improvements observed in HbA1c, blood pressure, and triglycerides across treatment arms.

Two decades of preclinical evidence. The pentadecapeptide BPC-157 has demonstrated tendon-to-bone healing, gut barrier restoration, and accelerated soft-tissue recovery across more than 200 animal-model studies. Mechanistic depth is robust; large-scale human RCT data remains limited.

GHK-Cu modulates over 4,000 human genes implicated in tissue remodeling, antioxidant defense, anti-inflammatory signaling, and skin repair. Endogenous plasma GHK declines roughly 60% between ages 20 and 60, paralleling the age-related decline in regenerative capacity.

2,539 adults with obesity randomized across four arms. Mean body-weight change at week 72: −22.5% on 15-mg tirzepatide, −19.5% on 10-mg, −15.0% on 5-mg, vs −2.4% on placebo. Largest weight reduction reported in a registrational obesity trial to date.

1,961 adults with overweight or obesity. Once-weekly 2.4-mg semaglutide produced a mean body-weight change of −14.9% at 68 weeks vs −2.4% on placebo. Concurrent improvements observed across cardiovascular risk markers including waist circumference, BP, and lipid profile.

17,604 adults with overweight or obesity and pre-existing cardiovascular disease, no diabetes. Once-weekly 2.4-mg semaglutide reduced major adverse cardiovascular events — non-fatal MI, non-fatal stroke, or CV death — by 20% over a mean follow-up of 39.8 months.

1,879 adults with type 2 diabetes randomized to once-weekly tirzepatide (5/10/15 mg) or 1-mg semaglutide. At 40 weeks, tirzepatide produced superior reductions in HbA1c (−2.30% on 15-mg) and body weight (−11.2 kg) versus semaglutide. First head-to-head GLP-1 vs dual-agonist trial.

410 adults with HIV-associated abdominal fat accumulation. Tesamorelin 2 mg daily produced a 15.2% mean reduction in visceral adipose tissue at 26 weeks vs a 5.0% increase on placebo. IGF-1 normalized within physiological range, supporting the GHRH-analog endocrine safety profile.

MOTS-c — a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA — regulates AMPK signaling, insulin sensitivity, and systemic metabolic homeostasis. Plasma MOTS-c declines with chronological age; circulating levels rise transiently with exercise.

Phase 2 obesity trial. 338 adults randomized to retatrutide or placebo. Mean body-weight change at 48 weeks: −17.5% on 12-mg retatrutide vs −2.1% on placebo. Dose-dependent improvements observed in HbA1c, blood pressure, and triglycerides across treatment arms.

Two decades of preclinical evidence. The pentadecapeptide BPC-157 has demonstrated tendon-to-bone healing, gut barrier restoration, and accelerated soft-tissue recovery across more than 200 animal-model studies. Mechanistic depth is robust; large-scale human RCT data remains limited.

GHK-Cu modulates over 4,000 human genes implicated in tissue remodeling, antioxidant defense, anti-inflammatory signaling, and skin repair. Endogenous plasma GHK declines roughly 60% between ages 20 and 60, paralleling the age-related decline in regenerative capacity.

2,539 adults with obesity randomized across four arms. Mean body-weight change at week 72: −22.5% on 15-mg tirzepatide, −19.5% on 10-mg, −15.0% on 5-mg, vs −2.4% on placebo. Largest weight reduction reported in a registrational obesity trial to date.

1,961 adults with overweight or obesity. Once-weekly 2.4-mg semaglutide produced a mean body-weight change of −14.9% at 68 weeks vs −2.4% on placebo. Concurrent improvements observed across cardiovascular risk markers including waist circumference, BP, and lipid profile.

17,604 adults with overweight or obesity and pre-existing cardiovascular disease, no diabetes. Once-weekly 2.4-mg semaglutide reduced major adverse cardiovascular events — non-fatal MI, non-fatal stroke, or CV death — by 20% over a mean follow-up of 39.8 months.

1,879 adults with type 2 diabetes randomized to once-weekly tirzepatide (5/10/15 mg) or 1-mg semaglutide. At 40 weeks, tirzepatide produced superior reductions in HbA1c (−2.30% on 15-mg) and body weight (−11.2 kg) versus semaglutide. First head-to-head GLP-1 vs dual-agonist trial.

410 adults with HIV-associated abdominal fat accumulation. Tesamorelin 2 mg daily produced a 15.2% mean reduction in visceral adipose tissue at 26 weeks vs a 5.0% increase on placebo. IGF-1 normalized within physiological range, supporting the GHRH-analog endocrine safety profile.

MOTS-c — a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA — regulates AMPK signaling, insulin sensitivity, and systemic metabolic homeostasis. Plasma MOTS-c declines with chronological age; circulating levels rise transiently with exercise.